- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Unpacking Amgen v. Sanofi
Aug 31st 2023
Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.
Latest Videos
Latest News
Bormioli Pharma’s Business Expands in United States
March 12th 2024
The European company has seen its business increase by 47% in North America.
J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs
March 7th 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans
March 7th 2024
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation
March 6th 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
March 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Nona Biosciences Partners with Boostimmune on ADC Development
February 28th 2024
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
AstraZeneca Completes Acquisition of Icosavax
February 21st 2024
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition
February 21st 2024
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
BioVaxys Acquires Full Portfolio of Former IMV
February 15th 2024
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
Novartis to Acquire MorphoSys for Roughly $2.9 Billion
February 8th 2024
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.